

**Supplementary table 4:** Summary of therapeutic regimens patients in our exploratory subcohort received.

<b>Treatment modalities</b>	<b>Number of patients Total: 109</b>
<b>Multimodal therapy</b>	<b>44</b>
<b>EPP + platinum/pemetrexed + IMRT</b>	<b>18</b>
<b>Surgery + chemotherapy</b>	<b>25</b>
- EPP + platinum/pemetrexed	10
- eP/D + platinum/pemetrexed	8
- EPP+ platinum/gemcitabine	4
- eP/D + platinum	1
- unspecified MCR surgery + platinum/taxane	1
- unspecified MCR surgery + platinum/epirubicine	1
<b>EPP + radiation therapy</b>	<b>1</b>
<b>Non-multimodal therapy</b>	<b>65</b>
<b>Chemotherapy</b>	<b>44</b>
- platinum/pemetrexed	28
- platinum/gemcitabine	6
- platinum/cyclophosphamide/epirubicine	3
- platinum/bortezomib	2
- pemetrexed	1
- unspecified chemotherapy	4
<b>Radiotherapy</b>	<b>1</b>
<b>Chemotherapy + radiotherapy</b>	<b>1</b>
<b>Surgery</b>	<b>5</b>
- EPP	3
- unspecified surgery	2
<b>Best supportive care</b>	<b>14</b>

EPP, extrapleural pneumonectomy; eP/D, extended pleural decortication; MCR, macroscopic complete resection